FOXO4-DRI vs Dasatinib + Quercetin

How do they actually differ?

Evidence tier: 3 for D+Q (Hickson 2019 and Justice 2019 Phase 1-2 trials in humans plus extensive preclinical literature); Tier 5 for FOXO4-DRI (Baar 2017 mouse proof-of-concept, no human trials).

FOXO4-DRI and Dasatinib-plus-Quercetin (D+Q) target the same biological category — senescent cells — but through structurally and mechanistically different routes. Senescent cells are non-proliferating but metabolically active "zombie cells" that accumulate with age, evade apoptosis, and secrete pro-inflammatory factors collectively called the senescence-associated secretory phenotype (SASP). FOXO4-DRI is a 47-amino-acid D-retro-inverso peptide engineered to disrupt the FOXO4-p53 protein-protein interaction that senescent cells use to keep p53 sequestered and apoptosis suppressed. By peeling p53 off FOXO4, the peptide releases p53 to drive apoptosis specifically in senescent cells while leaving healthy cells (where the FOXO4-p53 interaction is dispensable) untouched. The mechanism is single-target and highly selective; the trade-off is the molecule must be delivered by subcutaneous injection because peptides cannot survive oral digestion. D+Q is a combination of two small molecules: Dasatinib (an FDA-approved tyrosine kinase inhibitor used in chronic myeloid leukemia and acute lymphoblastic leukemia) and Quercetin (a natural flavonoid widely available as a supplement). Dasatinib inhibits anti-apoptotic ephrin-B and PI3K-AKT pathways that senescent cells depend on; Quercetin inhibits BCL-2-family anti-apoptotic proteins. The combination hits multiple senolytic dependencies simultaneously, with broader spectrum but predictably broader off-target potential. Both are administered as pulsed protocols (2-3 consecutive days every 4-12 weeks) reflecting senescent cells' slow re-accumulation. The matrix has the protocol, dosing, and access detail.

Who should choose FOXO4-DRI?

Evidence tier: 5 — speculative; no human trial data exists. Outside a clinical trial setting, the rational answer is no one.

FOXO4-DRI fits a narrow user profile in 2026: those participating in a clinical trial (none currently registered for the original peptide as of mid-2026), those whose physician has specific clinical reasoning for selecting this molecule over better-evidenced alternatives, or those accepting full research-tier risk in pursuit of mechanism-specific selectivity. The peptide's appeal is selectivity — the FOXO4-p53 binding interface is highly specific to senescent cells, and the D-retro-inverso engineering protects the peptide from rapid proteolysis without changing the binding profile. The Baar 2017 mouse data showed restoration of fur density, kidney function, and treadmill performance in aged mice with no apparent off-target effects. None of this has been replicated in humans, and the originating Peter de Keizer lab at the Hubrecht Institute has not published follow-up human work in the eight-plus years since the Cell paper. Research-supplier FOXO4-DRI carries no quality assurance, no purity certificate, and no FDA oversight — the molecule purchased online may or may not be the molecule used in the Baar paper, and theoretical p53-related cancer concerns from off-target activation cannot be ruled out without human safety data. The honest recommendation in 2026 is that FOXO4-DRI belongs to mechanism-curious users with high risk tolerance and trial-grade clinical supervision, not to general anti-aging consumers seeking practical senolytic therapy. Discuss any consideration with a physician familiar with both senolytic biology and oncology.

Who should choose Dasatinib + Quercetin?

Evidence tier: 3 — Hickson 2019 first-in-human diabetic kidney disease trial; Justice 2019 idiopathic pulmonary fibrosis pilot; multiple Mayo Clinic Phase 2 readouts ongoing.

D+Q fits patients with specific senolytic-relevant indications who have access to a physician familiar with senolytic clinical research and who can be appropriately monitored for the documented Dasatinib safety profile. The Mayo Clinic group (James Kirkland, Tamar Tchkonia, and colleagues) led the first translational human work — Hickson 2019 (EBioMedicine) was the first-in-human diabetic kidney disease pilot showing that a single senolytic dosing cycle reduced senescent-cell biomarkers in adipose and skin biopsies. Justice 2019 (EBioMedicine) was the parallel pilot in idiopathic pulmonary fibrosis demonstrating improved 6-minute walk distance and physical function. Patients with documented IPF, diabetic kidney disease, frailty, or other senescent-cell-accumulation indications who are evaluated by a senolytic-aware prescriber and who pass cardiac and hematologic screening are reasonable D+Q candidates. The Dasatinib component carries non-trivial risk: documented cardiac toxicity (pulmonary hypertension, QT prolongation, pleural effusion, fluid retention), gastrointestinal effects, bleeding risk, and immunosuppressive potential, even at the lower senolytic doses (100 mg single-day) compared to the chronic-leukemia dose (100-140 mg daily). Patients on anticoagulants, with cardiac history, or with active infection require careful supervision. Patients without a senolytic indication or without prescriber support should not pursue D+Q on the basis of general longevity interest; the off-target risk profile does not justify the speculative benefit in healthy aging. Discuss any senolytic consideration with a physician.

What does the evidence base actually say?

Evidence tier: 3 for D+Q, Tier 4-5 for FOXO4-DRI — Hickson 2019 and Justice 2019 anchor the human evidence; Baar 2017 anchors FOXO4-DRI mouse work; no head-to-head trial.

D+Q's clinical evidence is real but small in absolute terms relative to FDA-approved drug standards. Hickson 2019 (EBioMedicine) was the first-in-human pilot in diabetic kidney disease — single 3-day dosing cycle reduced SASP cytokines in plasma and reduced senescent-cell markers in adipose tissue and skin biopsies. Justice 2019 (EBioMedicine) was the IPF open-label pilot in 14 patients showing improved 6-minute walk distance and Short Physical Performance Battery scores. Multiple Mayo Clinic Phase 2 trials are running across frailty, kidney disease, IPF, and Alzheimer's disease with mixed-but-promising biomarker readouts and clinical-endpoint results staged through 2025-2027. The FOXO4-DRI evidence rests on Baar 2017 (Cell) — one influential paper showing that the engineered peptide restored fur density, kidney function, and treadmill performance in aged and chemotherapy-treated mice. Independent replication has been limited beyond the originating de Keizer lab; no Phase 1 human trial has been published. There is no head-to-head FOXO4-DRI-versus-D+Q trial in any indication. The mechanism comparison favors FOXO4-DRI for selectivity (single protein-protein interaction target) while D+Q has the broader spectrum (multiple anti-apoptotic dependencies). The clinical comparison favors D+Q decisively — one has documented human safety and biomarker response; the other has none. Anyone framing FOXO4-DRI as a clinically validated senolytic is overstating the evidence record by an order of magnitude.

Cost, access, and regulatory comparison

Evidence tier: 2 — pricing and regulatory status reflect April 2026 reality.

FOXO4-DRI is research-only worldwide. It is sold by peptide research suppliers as "for research use only" with explicit "not for human consumption" labeling. There is no FDA-approved FOXO4-DRI; there is no compounding pathway because there is no reference drug. The 503A and 503B compounding categories require an FDA-approved drug as reference; FOXO4-DRI has none. Research-supplier pricing runs ~$400-1,200 per dosing cycle (5-15 mg subcutaneously × 3 consecutive days, every 4-12 weeks). Quality, purity, and even peptide identity are unverified at the consumer level. D+Q access works through a different pathway. Dasatinib (Sprycel, Bristol-Myers Squibb) is FDA-approved for chronic myeloid leukemia (since 2006) and acute lymphoblastic leukemia (since 2010); generic dasatinib has been available since 2024 and runs $50-200 per 100 mg tablet at retail, much lower with insurance. Senolytic use is off-label and requires an oncology-channel prescription or an off-label-comfortable prescriber; some longevity-medicine clinics and senolytic-research-aware physicians will write off-label senolytic protocols for indication-eligible patients. Quercetin is over-the-counter as a dietary supplement, with quality varying widely; established brands run $15-40 per 1000 mg dose. Total D+Q cost runs ~$200-500 per dosing cycle. Both agents share the senolytic regulatory direction: no agent has full FDA senolytic approval; D+Q has the more advanced clinical pipeline. See the FDA Sprycel prescribing information for Dasatinib labeling and ClinicalTrials.gov for active senolytic trial registry.

Related on Peptide Story

• Longevity pillar guide
• FOXO4-DRI senolytic peptide deep dive
• FOXO4-DRI vs Fisetin comparison

References

• Baar MP, Brandt RMC, Putavet DA, et al. 2017. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. PMID 28340339
• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. 2019. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. PMID 31542391
• Justice JN, Nambiar AM, Tchkonia T, et al. 2019. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. PMID 30616998
• Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. 2018. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PMID 30279143